Contrarian Investors: Is Aurora Cannabis (TSX:ACB) Stock a Buy?

Aurora Cannabis Inc. (TSX:ACB)(NYSE:ACB) is down 50% in the past six months. Is this pot stock now oversold?

| More on:
question marks written reminders tickets

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

With equity markets trading near all-time highs, contrarian investors are searching for troubled stocks that have fallen out of favour and might offer a shot at some big gains on a turnaround.

Let’s take a look at Aurora Cannabis (TSX:ACB)(NYSE:ACB) to see if it deserves to be on your buy list today.

Tough run

Aurora Cannabis trades at $6.50 per share right now, down 50% in the past six months.

The drop is primarily due to a general pullback in the entire cannabis sector, as investors try to digest the fallout from companies running into trouble with regulators for not following the rules.

The absence of profits is also starting to force investors to rethink how much they want to pay for the shares of a marijuana company that continues to burn through cash.

The rapid emergence of the Canadian marijuana industry and pressures to get as much product to market as quickly as possible likely led to some of the bad decisions that have hit the sector in the past year. Namaste, Aphria, and, more recently, CannTrust have all run into trouble for issues ranging from self-dealing to growing plants in unlicensed facilities.

Investors might be wondering if these are isolated incidents or simply the start of more surprises to come from other players. As a result, many might be stepping back from pot stocks.

Regarding Aurora Cannabis, the company is one of the top two players in Canada and has grown significantly through a series of aggressive acquisitions. The recent extension of the slide in the stock price is due to weak results in the latest quarter.

Aurora missed revenue expectations, even after giving the market a heads up last month. In addition, the company pushed out its guidance for reaching profitability to some time in fiscal 2020. Net revenue in the most recent quarter came in at roughly $99 million compared to the $108 million expected by analysts who follow the stock.

Risk

Aurora Cannabis still has a market capitalization of $6.8 billion, which is steep for a company with annualized revenue of about $400 million and no profits. The downward trend in the stock might continue, as investors reset their expectations for the timing of the company’s move to profitability.

Determining the upside potential for earnings growth in the next few years is a challenge, and the market might not be willing to pay such a rich premium.

In addition, investors are not happy that the rollout of the recreational market in Canada has not gone very well, and people are hesitant to make big bets ahead of the launch of the edibles market. If edibles sales don’t go well, another steep leg to the downside could be on the way for Aurora Cannabis and its peers.

Opportunity

The negative sentiment across the industry might actually present an opportunity to get in while the stock is out of favour. There is a chance the edibles market will meet expectations. In that case, we could see cannabis stocks rally in early 2020 the way they did in January of 2019.

Should you buy?

As the marijuana industry matures, Aurora Cannabis is expected to be one of the eventual winners, given its size and its leadership position. If you are a cannabis bull, you might want to start nibbling, but I would probably wait for evidence the pullback has run its course before adding the shares to your portfolio.

There are other ways to play the growth of the cannabis industry without betting on the producers.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Andrew Walker has no position in any stock mentioned.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »